Skip to main navigation Skip to search Skip to main content

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

  • GARDENIA Study Group
  • Vita-Salute San Raffaele University
  • Icahn School of Medicine at Mount Sinai
  • ISCARE IVF
  • Hospital Universitario de la Princesa
  • Academic Medical Centre
  • King's College Hospital
  • University of Calgary
  • Yonsei University Mirae Campus
  • Medical University of Vienna
  • Roche Products Limited UK
  • Genentech Incorporated
  • Kiel University

Research output: Contribution to journal › Article › peer-review

87 Scopus citations

Fingerprint

Dive into the research topics of 'Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science